Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation

Journal of Medical Genetics

Volumn 44, Issue 6, 2007, Pages 393-396

  Uschkereit, Constanze ^a   Perez, Noelia ^b   De Torres, Carmen ^b   Küff, Maike ^a   Mora, Jaume ^b   Royer Pokora, Brigitte ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CATENIN BETA 1; DACTINOMYCIN; UNCLASSIFIED DRUG; VINCRISTINE; WT1 PROTEIN;

ALLELE; ARTICLE; BLASTEMA; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CASE REPORT; COMBINATION CHEMOTHERAPY; FEMALE; GENE MUTATION; GERM LINE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; KIDNEY TUBULE; KIDNEY TUMOR; MICRODISSECTION; MOLECULAR GENETICS; MUSCLE CELL; NEPHRECTOMY; NEPHROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; STROMA CELL; TUMOR CELL; WILD TYPE;

BASE SEQUENCE; BETA CATENIN; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GERM-LINE MUTATION; HUMANS; INFANT; MOLECULAR SEQUENCE DATA; WILMS TUMOR; WT1 PROTEINS;

EID: 34250738407     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.047530     Document Type: Article

References (11)

1. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-25.
2. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, Weirich A, Ludwig R, Royer-Pokora B. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA 1997;94:3972-7.
3. Shibata R, Hashigushi A, Sakamoto J, Yamada T, Umezawa A, Hata J. Correlation between a specific Wilms tumours suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT). J Med Genet 2002;39:e83.
4. Royer-Pokora B, Beier M, Henzler M, Alam R, Schumacher V, Weirich A, Huff V. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet 2004;127:249-57.
5. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2.
6. Maiti S, Alam R, Amos CI, Huff V. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000;60:6288-92.
7. Kusafuka T, Miao J, Kuroda S, Udatsu Y, Yoneda A. Codon 45 of the β-catenin gene, a specific mutational target site of Wilms' tumor. Int J Mol Med 2002;10:395-9.
8. Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, Reeve AE. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 2004;7:125-37.
9. Li C-M, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VVVS, Grundy PE, Fearon ER, D'Agati V, Licht JD, Tycko B. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004;165:1943-53.
10. Little S, Hanks S, King-Underwood L, Picton S, Cullinane C, Rapley E, Rahman N, Pritchard-Jones K. A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome. Pediatr Nephrol 2005;20:81-5.
11. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. Cell 1993;74:679-91.